BR9611563A - Compound pharmaceutical composition method of treating an inflammatory disease and assay to detect agrecanase inhibitors - Google Patents
Compound pharmaceutical composition method of treating an inflammatory disease and assay to detect agrecanase inhibitorsInfo
- Publication number
- BR9611563A BR9611563A BR9611563A BR9611563A BR9611563A BR 9611563 A BR9611563 A BR 9611563A BR 9611563 A BR9611563 A BR 9611563A BR 9611563 A BR9611563 A BR 9611563A BR 9611563 A BR9611563 A BR 9611563A
- Authority
- BR
- Brazil
- Prior art keywords
- agrecanase
- inhibitors
- assay
- treating
- detect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US668495P | 1995-11-14 | 1995-11-14 | |
| US64690296A | 1996-05-08 | 1996-05-08 | |
| US74343996A | 1996-11-01 | 1996-11-01 | |
| PCT/US1996/018382 WO1997018207A2 (en) | 1995-11-14 | 1996-11-13 | Novel macrocyclic compounds as metalloprotease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9611563A true BR9611563A (en) | 1999-03-02 |
Family
ID=27358171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9611563A BR9611563A (en) | 1995-11-14 | 1996-11-13 | Compound pharmaceutical composition method of treating an inflammatory disease and assay to detect agrecanase inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0863885A2 (en) |
| JP (1) | JP2000502050A (en) |
| CN (1) | CN1202161A (en) |
| BR (1) | BR9611563A (en) |
| CA (1) | CA2237524A1 (en) |
| CZ (1) | CZ144798A3 (en) |
| EE (1) | EE9800115A (en) |
| HR (1) | HRP960533A2 (en) |
| HU (1) | HUP0201479A2 (en) |
| IL (1) | IL124366A0 (en) |
| LV (1) | LV12167B (en) |
| MX (1) | MX9803851A (en) |
| NO (1) | NO982185L (en) |
| PL (1) | PL326714A1 (en) |
| SI (1) | SI9620120A (en) |
| SK (1) | SK63498A3 (en) |
| WO (1) | WO1997018207A2 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
| US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
| ZA9820B (en) * | 1997-01-07 | 1998-07-02 | Abbott Lab | Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion |
| US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| EA200001007A1 (en) | 1998-03-31 | 2001-04-23 | Дюпон Фармасьютикалз Компани | PHARMACEUTICAL PREPARATIONS FOR THE VISUALIZATION OF ANGIOGENIC DISORDERS |
| EP1084113A1 (en) | 1998-06-11 | 2001-03-21 | Du Pont Pharmaceuticals Company | A process for the preparation of macrocyclic metalloprotease inhibitors |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| BR9917079A (en) | 1998-12-18 | 2001-10-30 | Du Pont Pharm Co | Devitronectin receptor antagonist compounds, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition, diagnostic pharmaceutical composition, treatment method for rheumatoid arthritis, cancer and darthenosis in a patient, angiogenesis formation method therapy, cancer, new blood vessels, arteriosclerosis, darthenosis, ischemia and myocardial reperfusion injury in a patient |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| WO2000035887A2 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
| US6649377B1 (en) | 1999-05-10 | 2003-11-18 | Syntex (U.S.A.) Llc | Human aggrecanase and nucleic acid compositions encoding the same |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US6989139B2 (en) | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| CN1386118A (en) | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | Lactams substituted by cyclic succinates as inhibitors of A beta protein production |
| EP2087908B1 (en) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
| PE20030701A1 (en) | 2001-12-20 | 2003-08-21 | Schering Corp | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2005044780A1 (en) * | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative, addition salt thereof, and s1p receptor control agent |
| EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
| EP2429290B1 (en) | 2009-05-11 | 2014-01-01 | Purdue Research Foundation | Compounds and methods for treating aids and hiv infections |
| DK2710018T3 (en) | 2011-05-19 | 2022-03-21 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | MACROCYCLIC COMPOUNDS AS PROTEIN INKINASE INHIBITORS |
| CN102276546B (en) * | 2011-05-31 | 2014-06-25 | 中国科学院广州生物医药与健康研究院 | Compound used as aggrecanase modifier and application thereof |
| CN108623530B (en) * | 2016-09-18 | 2021-05-11 | 广西师范大学 | 1,2, 8-oxo-diazacyclononane-9-thioketone derivative and synthetic method and application thereof |
| CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
| US5427954A (en) * | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
-
1996
- 1996-11-13 EE EE9800115A patent/EE9800115A/en unknown
- 1996-11-13 CA CA002237524A patent/CA2237524A1/en not_active Abandoned
- 1996-11-13 CN CN96198327A patent/CN1202161A/en active Pending
- 1996-11-13 PL PL96326714A patent/PL326714A1/en unknown
- 1996-11-13 EP EP96943497A patent/EP0863885A2/en not_active Withdrawn
- 1996-11-13 WO PCT/US1996/018382 patent/WO1997018207A2/en not_active Application Discontinuation
- 1996-11-13 JP JP9519119A patent/JP2000502050A/en active Pending
- 1996-11-13 HU HU0201479A patent/HUP0201479A2/en unknown
- 1996-11-13 SI SI9620120A patent/SI9620120A/en unknown
- 1996-11-13 IL IL12436696A patent/IL124366A0/en unknown
- 1996-11-13 BR BR9611563A patent/BR9611563A/en not_active IP Right Cessation
- 1996-11-13 SK SK634-98A patent/SK63498A3/en unknown
- 1996-11-13 CZ CZ981447A patent/CZ144798A3/en unknown
- 1996-11-13 HR HR08/743,439A patent/HRP960533A2/en not_active Application Discontinuation
-
1998
- 1998-05-13 NO NO982185A patent/NO982185L/en unknown
- 1998-05-14 MX MX9803851A patent/MX9803851A/en unknown
- 1998-07-07 LV LVP-98-104A patent/LV12167B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0863885A2 (en) | 1998-09-16 |
| CN1202161A (en) | 1998-12-16 |
| WO1997018207A2 (en) | 1997-05-22 |
| WO1997018207A3 (en) | 1997-07-24 |
| NO982185D0 (en) | 1998-05-13 |
| NO982185L (en) | 1998-07-13 |
| LV12167A (en) | 1998-11-20 |
| PL326714A1 (en) | 1998-10-26 |
| IL124366A0 (en) | 1998-12-06 |
| HUP0201479A2 (en) | 2002-08-28 |
| HRP960533A2 (en) | 1998-04-30 |
| EE9800115A (en) | 1998-10-15 |
| SI9620120A (en) | 1999-06-30 |
| CA2237524A1 (en) | 1997-05-22 |
| CZ144798A3 (en) | 1998-10-14 |
| JP2000502050A (en) | 2000-02-22 |
| SK63498A3 (en) | 1999-01-11 |
| LV12167B (en) | 1999-03-20 |
| MX9803851A (en) | 1998-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9611563A (en) | Compound pharmaceutical composition method of treating an inflammatory disease and assay to detect agrecanase inhibitors | |
| BR9710372A (en) | Compound pharmaceutical composition and processes for the treatment of an inflammatory disease and diseases mediated by cliclooxygenase | |
| BR1100403A (en) | Compound and pharmaceutical composition of cox-2 inhibitors | |
| FI973974A (en) | Arylsulfonylhydroxamic acid derivatives as MMP and TNF inhibitors | |
| PT1003479E (en) | METHOD AND COMPOSITIONS FOR TREATING LOW-PHASE ALLERGIC REACTIONS AND INFLAMMATORY DISEASES | |
| BR9606520A (en) | Method to detect the amplification of a target sequence | |
| EE200300169A (en) | Method of use of cyclooxygenase-2 inhibitors for prevention of cardiovascular disease | |
| DE69633983D1 (en) | Inhibitors of micromosomal triglyceride transfer protein and method | |
| BR9604845A (en) | Process for extrusion of an extrusion composition and auxiliary processing system composition | |
| BR9407799A (en) | Composition of matter treatment method and pharmaceutical composition | |
| MA26935A1 (en) | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | |
| IL124559A0 (en) | Metalloproteinase inhibitors pharmaceutical compositions containing them and their pharmaceutical uses and methods and intermediates useful for their preparation | |
| EE200000488A (en) | Phospholipase enzyme inhibitors and pharmaceutical compositions | |
| NO982809D0 (en) | Drugs of thrombin inhibitors | |
| PT1275387E (en) | PREPARATION PROCESS OF PHENOFIBRATE PHARMACEUTICAL COMPOSITIONS PRESENTING HIGH BIODISPONIBILITY | |
| DE69822839D1 (en) | DERIVATIVES OF ARYLOXYARYLSULFONYLAMINO HYDROXYAMIC ACIDS | |
| BR9611377A (en) | Thrombin inhibitor of non-slow binding process to prepare the same pharmaceutical composition and use of the thrombin inhibitor | |
| ID21332A (en) | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA | |
| EE9800234A (en) | Method of treatment and pharmaceutical composition | |
| PT927183E (en) | SPIROCYLIC INHIBITORS OF METALOPROTEASES | |
| PL331339A1 (en) | Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase | |
| ID18382A (en) | PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS | |
| BR9602627A (en) | Compound method for inhibiting phosphodistyrase (pde) type iv method of treating or preventing a condition and pharmaceutical composition | |
| ATE198751T1 (en) | AZODERIVATES OF 5-AMINOSALICYLIC ACID FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | |
| NO944931D0 (en) | Use of 2-phenyl-3-arroylbenzothiophenes for inhibiting early sexual maturity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2029 DE 24/11/2009. |